Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Condition(s) targeted: Cancer

Intervention: itraconazole (Drug); voriconazole (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Jonsson Comprehensive Cancer Center

Official(s) and/or principal investigator(s):
Mary C. Territo, MD, Principal Investigator, Affiliation: Jonsson Comprehensive Cancer Center

RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation.

PURPOSE: This randomized clinical trial is studying voriconazole to see how well it works compared to itraconazole in preventing fungal infections in patients who are undergoing allogeneic hematopoietic stem cell transplantation.

Official title: Randomized Trial Of Safety And Tolerability Of Intravenous/Oral Voriconazole Versus Intravenous/Oral Itraconazole For Long-Term Antifungal Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplant Recipients

Study design: Supportive Care, Randomized, Active Control

Detailed description: OBJECTIVES:

- Compare the safety and tolerability of voriconazole vs itraconazole for the prevention

of fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation.

OUTLINE: This is a randomized study. Patients are stratified according to donor type (related vs unrelated). Patients are randomized to 1 of 2 treatment arms.

- Arm I: Beginning after allogeneic hematopoietic stem cell transplantation (AHSCT),

patients receive voriconazole IV twice daily on days 1-14 and then orally* twice daily on days 15-100.

- Arm II: Beginning after AHSCT, patients receive itraconazole IV twice daily on days 1-2,

once daily on days 3-14, and then orally* twice daily on days 15-100.

NOTE: *Patients unable to tolerate oral medication may continue IV medication beyond day 14.

In both arms, treatment continues in the absence of unacceptable toxicity or an invasive fungal infection. Patients requiring corticosteroid therapy for graft-versus-host disease continue to receive voriconazole or itraconazole beyond day 100.

Patients are followed until day 180 post-transplantation.

PROJECTED ACCRUAL: A total of 150 patients (75 per treatment arm) will be accrued for this study.

Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

DISEASE CHARACTERISTICS:

- Undergoing allogeneic hematopoietic stem cell transplantation

- No invasive yeast infection within the past 8 weeks

- Colonized or superficial infection allowed

- No documented or probable aspergillus or mold infection within the past 8 weeks

- Patients with a history of candidemia must have negative blood cultures and no

clinical signs of candidemia

PATIENT CHARACTERISTICS:

Age

- 12 and over

Performance status

- Not specified

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Not specified

Other

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No prior allergy or intolerance to imidazoles or azoles (e. g., fluconazole,

itraconazole, voriconazole, ketoconazole, miconazole, or clotrimazole)

PRIOR CONCURRENT THERAPY:

Biologic therapy

- See Disease Characteristics

Chemotherapy

- Not specified

Endocrine therapy

- Not specified

Radiotherapy

- Not specified

Surgery

- Not specified

Other

- At least 1 week since prior amphotericin B or fluconazole for candidemia

- No concurrent therapy with any of the following:

- Rifampin

- Rifabutin

- Phenobarbital

- Phenytoin

- Carbamazepine

- Oral midazolam

- Triazolam

- Terfenadine

- Astemizole

- Concurrent topical antifungal agents for superficial fungal infections allowed

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California 90095-1678, United States

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: January 2004
Last updated: May 23, 2008